Subjects -> MEDICAL SCIENCES (Total: 8186 journals)
    - ALLERGOLOGY AND IMMUNOLOGY (205 journals)
    - ANAESTHESIOLOGY (105 journals)
    - CARDIOVASCULAR DISEASES (334 journals)
    - CHIROPRACTIC, HOMEOPATHY, OSTEOPATHY (19 journals)
    - COMMUNICABLE DISEASES, EPIDEMIOLOGY (227 journals)
    - DENTISTRY (266 journals)
    - DERMATOLOGY AND VENEREOLOGY (162 journals)
    - EMERGENCY AND INTENSIVE CRITICAL CARE (121 journals)
    - ENDOCRINOLOGY (149 journals)
    - FORENSIC SCIENCES (43 journals)
    - GASTROENTEROLOGY AND HEPATOLOGY (178 journals)
    - GERONTOLOGY AND GERIATRICS (125 journals)
    - HEMATOLOGY (160 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (178 journals)
    - LABORATORY AND EXPERIMENTAL MEDICINE (90 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2230 journals)
    - NURSES AND NURSING (331 journals)
    - OBSTETRICS AND GYNECOLOGY (199 journals)
    - ONCOLOGY (355 journals)
    - OPHTHALMOLOGY AND OPTOMETRY (135 journals)
    - ORTHOPEDICS AND TRAUMATOLOGY (150 journals)
    - OTORHINOLARYNGOLOGY (76 journals)
    - PATHOLOGY (96 journals)
    - PEDIATRICS (254 journals)
    - PHYSICAL MEDICINE AND REHABILITATION (153 journals)
    - PSYCHIATRY AND NEUROLOGY (800 journals)
    - RADIOLOGY AND NUCLEAR MEDICINE (182 journals)
    - RESPIRATORY DISEASES (109 journals)
    - RHEUMATOLOGY (76 journals)
    - SPORTS MEDICINE (77 journals)
    - SURGERY (388 journals)
    - UROLOGY, NEPHROLOGY AND ANDROLOGY (151 journals)

HEMATOLOGY (160 journals)                     

Showing 1 - 122 of 122 Journals sorted alphabetically
Acta Angiologica     Open Access   (Followers: 3)
Adipocyte     Open Access  
Advances in Hematology     Open Access   (Followers: 13)
Africa Sanguine     Full-text available via subscription  
American Journal of Hematology     Hybrid Journal   (Followers: 46)
Anemia     Open Access   (Followers: 6)
Annals of Hematology     Hybrid Journal   (Followers: 14)
Arteriosclerosis, Thrombosis and Vascular Biology     Full-text available via subscription   (Followers: 25)
Artery Research     Hybrid Journal   (Followers: 4)
Artificial Cells, Nanomedicine and Biotechnology     Hybrid Journal   (Followers: 3)
ASAIO Journal     Hybrid Journal   (Followers: 2)
Best Practice & Research Clinical Haematology     Hybrid Journal   (Followers: 5)
Blood     Hybrid Journal   (Followers: 296)
Blood Advances     Open Access   (Followers: 9)
Blood and Lymphatic Cancer : Targets and Therapy     Open Access   (Followers: 7)
Blood Cancer Journal     Open Access   (Followers: 21)
Blood Cells, Molecules, and Diseases     Hybrid Journal   (Followers: 5)
Blood Coagulation & Fibrinolysis     Hybrid Journal   (Followers: 27)
Blood Pressure     Open Access   (Followers: 1)
Blood Pressure Monitoring     Hybrid Journal   (Followers: 2)
Blood Reviews     Hybrid Journal   (Followers: 20)
BMJ Open Diabetes Research & Care     Open Access   (Followers: 23)
Bone Marrow Transplantation     Hybrid Journal   (Followers: 15)
British Journal of Haematology     Hybrid Journal   (Followers: 54)
Canadian Journal of Diabetes     Hybrid Journal   (Followers: 9)
Case Reports in Hematology     Open Access   (Followers: 10)
Clinical and Applied Thrombosis/Hemostasis     Open Access   (Followers: 28)
Clinical Diabetes     Full-text available via subscription   (Followers: 30)
Clinical Diabetes and Endocrinology     Open Access   (Followers: 14)
Clinical Lymphoma & Myeloma     Full-text available via subscription   (Followers: 2)
Conquest : The Official Journal of Diabetes Australia     Full-text available via subscription   (Followers: 1)
Current Angiogenesis     Hybrid Journal   (Followers: 1)
Current Diabetes Reports     Hybrid Journal   (Followers: 14)
Current Diabetes Reviews     Hybrid Journal   (Followers: 13)
Current Hematologic Malignancy Reports     Hybrid Journal   (Followers: 2)
Current Opinion in Hematology     Hybrid Journal   (Followers: 14)
Cytotherapy     Full-text available via subscription   (Followers: 1)
Der Diabetologe     Hybrid Journal  
Diabetes     Full-text available via subscription   (Followers: 262)
Diabetes aktuell     Hybrid Journal   (Followers: 2)
Diabetes and Vascular Disease Research     Hybrid Journal   (Followers: 8)
Diabetes Care     Full-text available via subscription   (Followers: 285)
Diabetes Case Reports     Open Access  
Diabetes Educator     Hybrid Journal   (Followers: 10)
Diabetes Research and Clinical Practice     Hybrid Journal   (Followers: 18)
Diabetes Spectrum     Full-text available via subscription   (Followers: 14)
Diabetes Technology & Therapeutics     Hybrid Journal   (Followers: 8)
Diabetes Therapy     Open Access   (Followers: 13)
Diabetic Foot & Ankle     Open Access   (Followers: 9)
Diabetic Medicine     Hybrid Journal   (Followers: 93)
Diabetologia     Hybrid Journal   (Followers: 107)
Diabetologie und Stoffwechsel     Hybrid Journal  
Egyptian Journal of Hematology and Bone Marrow Transplantation     Open Access   (Followers: 9)
eJHaem     Open Access   (Followers: 1)
European Journal of Haematology     Hybrid Journal   (Followers: 12)
Experimental Hematology     Hybrid Journal   (Followers: 3)
Experimental Hematology & Oncology     Open Access   (Followers: 6)
Expert Review of Hematology     Hybrid Journal   (Followers: 4)
Fluids and Barriers of the CNS     Open Access   (Followers: 1)
Haematologica - the Hematology journal     Open Access   (Followers: 35)
Haemophilia     Hybrid Journal   (Followers: 15)
Hematologia     Full-text available via subscription   (Followers: 3)
Hematology     Open Access   (Followers: 9)
Hematology, Transfusion and Cell Therapy     Open Access   (Followers: 2)
Hemodialysis International     Hybrid Journal   (Followers: 3)
Hepatitis Monthly     Open Access   (Followers: 3)
Immunohematology : Journal of Blood Group Serology and Molecular Genetics     Hybrid Journal   (Followers: 3)
Indian Journal of Hematology and Blood Transfusion     Hybrid Journal   (Followers: 1)
Info Diabetologie     Full-text available via subscription  
InFo Hämatologie + Onkologie : Interdisziplinäre Fortbildung von Ärzten für Ärzte     Full-text available via subscription  
Integrated Blood Pressure Control     Open Access   (Followers: 1)
International Blood Research & Reviews     Open Access  
International Journal of Clinical Transfusion Medicine     Open Access   (Followers: 3)
International Journal of Diabetes in Developing Countries     Hybrid Journal   (Followers: 5)
International Journal of Diabetes Research     Open Access   (Followers: 6)
International Journal of Hematology     Hybrid Journal   (Followers: 3)
International Journal of Hematology Research     Open Access   (Followers: 2)
International Journal of Laboratory Hematology     Hybrid Journal   (Followers: 24)
JMIR Diabetes     Open Access  
Journal of Blood Medicine     Open Access  
Journal of Cerebral Blood Flow & Metabolism     Hybrid Journal   (Followers: 3)
Journal of Diabetes     Open Access   (Followers: 12)
Journal of Diabetes and its Complications     Hybrid Journal   (Followers: 13)
Journal of Diabetes and Metabolic Disorders     Open Access   (Followers: 6)
Journal of Diabetes Investigation     Open Access   (Followers: 6)
Journal of Diabetes Mellitus     Open Access   (Followers: 4)
Journal of Hematological Malignancies     Open Access  
Journal of Hematology and Transfusion Medicine     Open Access   (Followers: 1)
Journal of Hematopathology     Hybrid Journal   (Followers: 3)
Journal of Pediatric Hematology/Oncology     Hybrid Journal   (Followers: 6)
Journal of Social Health and Diabetes     Open Access  
Journal of Thrombosis and Haemostasis     Hybrid Journal   (Followers: 52)
Journal of Thrombosis and Thrombolysis     Hybrid Journal   (Followers: 30)
Leukemia     Hybrid Journal   (Followers: 23)
Leukemia and Lymphoma     Hybrid Journal   (Followers: 13)
Leukemia Research     Hybrid Journal   (Followers: 9)
Leukemia Research Reports     Open Access   (Followers: 1)
Leukemia Supplements     Full-text available via subscription  
Nederlands Tijdschrift voor Diabetologie     Hybrid Journal  
Nutrition & Diabetes     Open Access   (Followers: 18)
Oncohematology     Open Access   (Followers: 1)
Open Diabetes Journal     Open Access  
Open Hematology Journal     Open Access   (Followers: 1)
Open Hypertension Journal     Open Access  
Open Journal of Blood Diseases     Open Access  
Pediatric Blood & Cancer     Hybrid Journal   (Followers: 6)
Pediatric Hematology Oncology Journal     Open Access   (Followers: 3)
Peritoneal Dialysis International     Hybrid Journal  
Plasmatology     Open Access   (Followers: 1)
Platelets     Hybrid Journal   (Followers: 2)
Practical Diabetes     Hybrid Journal   (Followers: 4)
Primary Care Diabetes     Hybrid Journal   (Followers: 16)
Research and Practice in Thrombosis and Haemostasis     Open Access   (Followers: 2)
Revista Cubana de Hematología, Inmunología y Hemoterapia     Open Access  
Seminars in Hematology     Hybrid Journal   (Followers: 9)
Seminars in Thrombosis and Hemostasis     Hybrid Journal   (Followers: 28)
The Lancet Haematology     Full-text available via subscription   (Followers: 43)
Therapeutic Advances in Hematology     Hybrid Journal  
Thrombosis & Haemostasis     Hybrid Journal   (Followers: 105)
Thrombosis Research     Hybrid Journal   (Followers: 30)
Transplantation and Cellular Therapy     Hybrid Journal   (Followers: 11)
Veins and Lymphatics     Open Access   (Followers: 1)

           

Similar Journals
Journal Cover
Clinical Lymphoma Myeloma and Leukemia
Number of Followers: 6  
 
  Hybrid Journal Hybrid journal (It can contain Open Access articles)
ISSN (Print) 2152-2650 - ISSN (Online) 2152-2669
This journal is no longer being updated because:
    the publisher no longer provides RSS feeds
  • Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin
           Lymphoma

    • Free pre-print version: Loading...

      Authors: Matthew Mei; Ni-Chun Tsai, Joycelynne Palmer, Saro Armenian, Robert Chen, Steven Rosen, Stephen Forman, Leslie Popplewell, Larry Kwak, Peter Martin, Kami Maddocks, David Bond, Alex F. Herrera
      Abstract: Brentuximab vedotin (BV) is an antibody-drug conjugate that delivers monomethyl auristatin E (MMAE) to CD30+ cells and is safe and effective in relapsed/refractory (r/r) Hodgkin lymphoma (HL). Although most patients respond to BV, only a minority will obtain a complete response (CR), and almost all patients eventually progress.Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor highly active in multiple subtypes of non-Hodgkin lymphoma; limited data exist regarding its use in HL. It irreversibly inhibits interleukin-2-inducible kinase (ITK) with Th1 based immune responses.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-04-10
      DOI: 10.1016/j.clml.2024.03.013
       
  • Burden of Infection in Patients With and Without Secondary
           Immunodeficiency Disease Following Diagnosis of a Mature B Cell Malignancy
           

    • Free pre-print version: Loading...

      Authors: Joshua Richter; Matthew S. Davids, Colin Anderson-Smits, Marta Kamieniak, Kaili Ren, Michael Hull, Jasjit K. Multani, Drishti Shah, Csaba Siffel
      Abstract: Patients with mature B cell malignancies such as chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), multiple myeloma (MM), and non-Hodgkin's lymphoma (NHL) are at risk of developing secondary immunodeficiency disease (SID) owing to the underlying disease process and the use of anti-cancer treatments with immunosuppressive effects.1 Patients with mature B cell malignancies and SID are susceptible to severe, recurrent, or persistent infections that result in substantial morbidity and increased mortality, as well as a considerable economic burden.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-04-09
      DOI: 10.1016/j.clml.2024.04.002
       
  • Serum free light chain kinetics is predictive of renal response in myeloma
           patients with renal impairment– an ALLG trial of
           carfilzomib-dexamethasone therapy in frontline and relapse.

    • Free pre-print version: Loading...

      Authors: P. Joy Ho; Andrew Spencer, Peter Mollee, Christian E. Bryant, Anoop K. Enjeti, Noemi Horvath, Belinda E. Butcher, Judith Trotman, Simon Gibbs, Douglas E. Joshua
      Abstract: Renal impairment (RI) confers adverse prognosis in myeloma; its reversal and avoidance of dialysis are crucial. We investigated whether serum free light chain (SFLC) measurements can predict renal outcome, to enable change in therapy to optimise prognosis and avoid dialysis.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-04-06
      DOI: 10.1016/j.clml.2024.04.001
       
  • Real-world multicenter study of PD-1 blockade in HIV-associated classical
           Hodgkin lymphoma across the United States

    • Free pre-print version: Loading...

      Authors: Kathryn Lurain; Talal El Zarif, Ramya Ramaswami, Amin H. Nassar, Elio Adib, Noha Abdel-Wahab, Nikita Chintapally, Claire E. Drolen, Tatyana Feldman, Tarek Haykal, Caroline A. Nebhan, Swetha Kambhampati, Mingjia Li, Arjun Mittra, Michael Lorentsen, Chul Kim, Alexandra Drakaki, Michael Morse, Douglas B. Johnson, Ankit Mangla, Christopher Dittus, Praful Ravi, Robert A. Baiocchi, Elizabeth Y. Chiao, Paul G. Rubinstein, Sarvari V. Yellapragada, Ann S. LaCasce, Guru P. Sonpavde, Abdul Rafeh Naqash, Alex F. Herrera
      Abstract: Despite a higher risk of classical Hodgkin lymphoma (cHL) in people with HIV and the demonstrated safety and efficacy of PD-1 blockade in cHL, there are limited data on the use of these agents in HIV-associated cHL (HIV-cHL).
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-04-05
      DOI: 10.1016/j.clml.2024.03.011
       
  • Clinical significance of cytomegalovirus reactivation in patients with
           plasma cell dyscrasia who were treated with anti-CD38 monoclonal antibody:
           A retrospective analysis in a single institution

    • Free pre-print version: Loading...

      Authors: Naohiro Matsunaga; Tomotaka Suzuki, Nozomi Nishitarumizu, Yoko Nakanishi, Aki Kondo, Yukiyasu Kato, Toru Ebina, Yoshiaki Marumo, Tomoyuki Nakamura, Takahiro Nakashima, Shiori Kinoshita, Tomoko Narita, Masaki Ri, Shigeru Kusumoto, Hirokazu Komatsu, Shinsuke Iida
      Abstract: Anti-CD38 monoclonal antibodies (mAbs) have improved the prognosis of patients with plasma cell dyscrasia (PCD), but are also associated with increased infectious adverse events. Cytomegalovirus (CMV) is a common latent pathogen that is reactivated in immunocompromised individuals. Although CMV reactivation has mostly been reported after high-dose chemotherapy followed by stem cell transplantation in patients with PCD, cases of reactivation during anti-CD38 mAb therapy have been reported recently.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-03-30
      DOI: 10.1016/j.clml.2024.03.012
       
  • Mantle Cell Lymphoma under the scope of personalized medicine: perspective
           and directions

    • Free pre-print version: Loading...

      Authors: Lara Gallucci Figorelle; Peterson Tiago Galvão, Felipe Matheus Ribeiro de Lima, Patricia Marimon, Nathalia Pentagna, Cristiane Milito, Rony Schaffel, Katia Carneiro
      Abstract: Mantle Cell Lymphoma (MCL) is a rare, incurable non-Hodgkin's lymphoma characterized by naive B cells infiltrating the lymphoid follicle's mantle zone. A key feature of MCL is the cytogenetic abnormality t(11;14) (q13:q14), found in 95% of cases, leading to Cyclin D1 overexpression resulting in uncontrolled cell cycle progression and genetic instability. Occasionally, Cyclin D2 or D3 overexpression can substitute for Cyclin D1, causing similar effects. The transcription factor SOX11 is a hallmark of classical Cyclin D1-positive MCL and also in cases without the typical t(11;14) abnormality, making it an important diagnostic marker.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-03-27
      DOI: 10.1016/j.clml.2024.03.010
       
  • SOHO State of the Art Updates and Next Questions Pre-emptive Therapy at
           Molecular Measurable Residual Disease Failure in Acute Myeloid Leukaemia

    • Free pre-print version: Loading...

      Authors: Aditya Tedjaseputra; Nigel Russell, Richard Dillon
      Abstract: Molecular measurable residual disease (MRD, e.g., by real-time quantitative polymerase chain reaction, RT-qPCR), is an integral part of response assessment in acute myeloid leukaemia (AML) with established prognostic and evolving therapeutic significance. MRD failure can occur through several pathways (namely MRD persistence at the end of treatment at a high level, MRD progression from a low level or MRD re-emergence during follow up; the latter two constitute MRD relapse as defined by the European Leukaemia Net) and is clinically actionable, with survival benefit reported in AML subgroups.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-03-26
      DOI: 10.1016/j.clml.2024.03.009
       
  • Practical Aspects of Immunotherapy: A Report from the 20th International
           Myeloma Society (IMS) Annual Meeting

    • Free pre-print version: Loading...

      Authors: Noopur S. Raje; Adam D Cohen, Krina K Patel, Niels W.C.J. van de Donk, Joshua Richter, Jesus San-Miguel
      Abstract: Immunotherapeutic strategies, specifically T-cell redirected therapies have been transformative in the context of multiple myeloma (MM). With the approval of two chimeric antigen receptor T-cell (CAR-T) drug products and three bispecific antibodies/T-cell engagers (bsAbs/TCEs) in relapsed/refractory MM (RRMM), the 20th annual IMS meeting dedicated a session to the practical aspects of these therapies. Here, we highlight the discussion during this session including the role of CAR-T and bsAb therapies in frontline MM treatment, management of acute toxicities, prevention and management of infections, and finally treatment sequencing of T-cell redirected therapies.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-03-21
      DOI: 10.1016/j.clml.2024.03.005
       
  • SOHO State of the Art Updates and Next Questions Updates on Building Your
           CAR-T Cell Program

    • Free pre-print version: Loading...

      Authors: Timothy J Voorhees; Evandro Bezerra, Nathan Denlinger, Samantha Jaglowski, Marcos de Lima
      Abstract: The field of Cellular Immunotherapy has rapidly evolved over the past decade. Since the first Food and Drug Administration (FDA) approval of tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta) in 2017, the list of approvals expanded to include brexucabtagene autoleucel (Tecartus) in 2020, lisocabtagene maraleucel (Breyanzi) in 2021, idacabtagene vicleucel (Abecma) in 2021, and ciltacabtagene autoleucel (Carvykti) in 2022.1-9 In addition, cellular therapies are being studied earlier in the treatment course for patients with relapsed lymphoma and multiple myeloma.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-03-18
      DOI: 10.1016/j.clml.2024.03.007
       
  • SOHO State of the Art Updates and Next Questions An Update on Higher Risk
           Myelodysplastic Syndromes

    • Free pre-print version: Loading...

      Authors: Michael J. Hochman; Amy E. DeZern
      Abstract: High-risk myelodysplastic neoplasms (abbreviated HR-MDS) are a heterogenous group of clonal myeloid-lineage malignancies often characterized by high-risk genetic lesions, increased blood transfusion needs, constitutional symptoms, elevated risk of progression to acute myeloid leukemia (AML) and therapeutic need for bone marrow transplantation. Use of blast percentage and other morphologic features to define MDS subtypes is rapidly shifting to incorporate genetics, resulting in a subset of former HR-MDS patients now being considered as AML in presence of leukemia-defining genetic alterations.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-03-18
      DOI: 10.1016/j.clml.2024.03.006
       
  • CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE
           MYELOMA AFTER EXPOSURE TO LENALIDOMIDE IN FIRST LINE OF THERAPY: A SINGLE
           CENTER DATABASE REVIEW IN GREECE

    • Free pre-print version: Loading...

      Authors: Efstathios Kastritis; Ioannis Ntanasis-Stathopoulos, Foteini Theodorakakou, Magdalini Migkou, Maria Roussou, Panagiotis Malandrakis, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Despina Fotiou, Vassiliki Spiliopoulou, Maria Gavriatopoulou, Sachin Patel, Istvan Majer, Christos Boukis, Andriani Fetani, Meletios A. Dimopoulos, Evangelos Terpos
      Abstract: Most patients with multiple myeloma (MM) will develop disease recurrence during first-line (1L) treatment and eventually to subsequent treatments. These patients become refractory to treatment (developing relapsed/refractory MM [RRMM]), with disease severity and duration of remission worsening with each successive relapse.1, 2
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-03-18
      DOI: 10.1016/j.clml.2024.03.003
       
  • SOHO State of the Art Updates and Next Questions Diagnosis and Management
           of Monoclonal Gammopathy of Undetermined Significance and Smoldering
           Multiple Myeloma

    • Free pre-print version: Loading...

      Authors: Timothy Schmidt; Zhubin Gahvari, Natalie S. Callander
      Abstract: Monoclonal proteins are common, with a prevalence in the United States around 5% and the incidence increases with age. Although most patients are asymptomatic, the vast majority of cases are caused by a clonal plasma cell disorder. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) are asymptomatic precursor conditions with variable risk of progression to multiple myeloma (MM). In recent years, significant progress has been made to better understand the factors that lead to the development of symptoms and progression to myeloma.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-03-16
      DOI: 10.1016/j.clml.2024.03.008
       
  • BCMA directed Bispecific Antibody induced tumour flare in Multiple Myeloma

    • Free pre-print version: Loading...

      Authors: Dr. Chandramouli Nagarajan; Dr. Thomas G Martin
      Abstract: Bispecific antibodies have emerged as highly effective treatments for multiple myeloma patients even in late relapse when all available novel agents have been exhausted. However, they cause some adverse events of special interest (AESI) that treating physicians need to be aware of. AESIs like CRS and ICANS are reasonably wellcaptured and reported in most early phase and pivotal studies and their management strategies have been well discussed, debated, and published. However, tumour flare reactions caused by BsAb induced T-cell activation and associated inflammatory reaction have hardly been reported in the pivotal trials of their use in Myeloma.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-03-16
      DOI: 10.1016/j.clml.2024.03.002
       
  • Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and
           Outcomes

    • Free pre-print version: Loading...

      Authors: Luis E. Aguirre; Akriti Jain, Somedeb Ball, Najla Al Ali, Virginia O. Volpe, Sara Tinsley-Vance, David Sallman, Kendra Sweet, Jeffrey Lancet, Eric Padron, Seongseok Yun, Andrew Kuykendall, Rami Komrokji
      Abstract: Myelofibrosis (MF) is a clonal disorder of hematopoiesis and the most aggressive subtype among classical BCR::ABL1 negative myeloproliferative neoplasms (MPN). Approximately 90% of patients harbor a mutation affecting JAK2, MPL, or CALR signaling which results in constitutive activation of the JAK/STAT pathway and culminates in proliferative and dysfunctional blood cell production, extramedullary hematopoiesis, and constitutional symptoms. Conversely, 5-10% of patients are deemed to be “triple-negative” (TN), a designation associated with poor prognosis (1).
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-03-10
      DOI: 10.1016/j.clml.2024.03.001
       
  • Average temperature as a marker of lymphoma-associated HLH.

    • Free pre-print version: Loading...

      Authors: Cameron Clark; Jack Goddard, Rachel Tattersall, Nick Morley
      Abstract: Haemophagocytic Lymphohistiocytosis (HLH) is a rare and poorly recognised systemic, hyperinflammatory clinical syndrome associated with a high mortality in those affected.1 In its primary form, HLH is characterised by the presence of genetic abnormalities and typically affects children. Secondary HLH is an altogether more heterogenous condition associated with autoimmune disease, infection and malignancy.2 The pathophysiology of secondary HLH represents immune dysfunction and dysregulation resulting in a continuous cycle of hyperinflammation causing widespread tissue injury.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-03-10
      DOI: 10.1016/j.clml.2024.02.016
       
  • Prevalence and consequences of a delayed diagnosis in multiple myeloma: A
           single institution experience

    • Free pre-print version: Loading...

      Authors: Paola Negrete-Rodríguez; Moisés Manuel Gallardo-Pérez, Olivia Lira-Lara, Miranda Melgar-de-la-Paz, Luis Enrique Hamilton-Avilés, Guillermo Ocaña-Ramm, Max Robles-Nasta, Daniela Sánchez-Bonilla, Juan Carlos Olivares-Gasca, María-Victoria Mateos, Guillermo J. Ruiz-Delgado, Guillermo J. Ruiz-Argüelles
      Abstract: Multiple myeloma (MM) is a disease with unspecific initial symptoms which may lead into a delay in the diagnosis, seemingly increasing the risk of complications and in turn reducing the overall survival (OS).
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-03-09
      DOI: 10.1016/j.clml.2024.03.004
       
  • SOHO State of the Art Updates and Next Questions Novel Agents and the
           Diminishing Role of Allogeneic Stem Cell Transplant in B-Acute
           Lymphoblastic Leukemia

    • Free pre-print version: Loading...

      Authors: Wei-Ying JEN; Elias JABBOUR, Hagop M. KANTARJIAN, Nicholas J. SHORT
      Abstract: Outcomes of patients with B-acute lymphoblastic leukemia (B-ALL) have improved remarkably in the past decade. This has largely been due to the development and introduction of novel immunotherapies such as blinatumomab, inotuzumab ozogamicin, chimeric antigen receptor T (CAR-T) cells, highly potent tyrosine kinase inhibitors, and improved risk stratification, including better understanding of high risk genomic subgroups and better methods of measurable residual disease (MRD) detection. Historically, allogeneic stem cell transplant (allo-SCT) has been the consolidative treatment of choice in first complete remission for fit adults with B-ALL.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-03-05
      DOI: 10.1016/j.clml.2024.02.017
       
  • SOHO State of the Art Updates and Next Questions Early Intervention in
           Myelofibrosis: Where are we and Does It Matter'

    • Free pre-print version: Loading...

      Authors: Abdulraheem Yacoub; Nicole Twardowski, Alec Britt, Nour Shraim
      Abstract: Historically, therapeutic clinical trials in myelofibrosis have predominantly focused on targeting patients with higher-risk disease who are at risk of increased morbidity and mortality. The endpoints have been designed to target regularly measured disease parameters that are of immediate pertinence to patient's welfare including splenic volume reduction, and symptom reduction. These efforts have resulted in meaningful and measurable improvements in disease parameters in these high-risk study populations and multiple FDA approved agents.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-03-05
      DOI: 10.1016/j.clml.2024.02.015
       
  • Using Proton Pump Inhibitors is not Associated with Adverse Outcomes in
           Patients with Chronic Myeloid Leukemia Treated with Dasatinib

    • Free pre-print version: Loading...

      Authors: Fadi G. Haddad; Cedric Nasnas, Koji Sasaki, Shilpa Paul, Ghayas C. Issa, Caitlin Rausch, Elias Jabbour, Hagop Kantarjian
      Abstract: Treatment with the BCR::ABL1 tyrosine kinase inhibitors (TKIs) has markedly improved the outcome of patients with chronic myeloid leukemia (CML). These oral therapies are convenient but raise the concern of potential gastrointestinal malabsorption due to drug-drug interactions. This could compromise the treatment efficacy and result in adverse events (e.g., increasing the concentration of a drug beyond the therapeutic index).1 An important factor influencing TKI absorption is the change in gastric pH.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-02-29
      DOI: 10.1016/j.clml.2024.02.014
       
  • PORT: A Randomized, Cross-over, Phase 2 Study of Melflufen Peripheral
           versus Central Intravenous Administration in Patients with
           Relapsed/Refractory Multiple Myeloma

    • Free pre-print version: Loading...

      Authors: Ludek Pour; Ilina Micheva, Ganna Usenko, Gabor Mikala, Tamas Masszi, Kameliya Simeonova, Marcus Thuresson, Gunilla Huledal, Stefan Norin, Nicolaas A. Bakker, Jiri Minarik
      Abstract: Although recent therapeutic advances have significantly improved survival among patients with multiple myeloma,1 it is still considered to be an incurable disease for the majority of patients. With current therapeutic practice with triplet or quadruplet therapies recommended both at initial treatment and in later lines,2,3 patients at second or later relapses are being increasingly refractory to multiple classes of agents.4 Additionally, outcomes for patients with triple-refractory disease remain poor.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-02-22
      DOI: 10.1016/j.clml.2024.02.012
       
  • Financial toxicity, time toxicity, and quality of life in multiple myeloma

    • Free pre-print version: Loading...

      Authors: Rahul Banerjee; Andrew J. Cowan, Marivel Ortega, Constance Missimer, Paul A. Carpenter, Masumi Ueda Oshima, Rachel B. Salit, Phuong T. Vo, Catherine J. Lee, Rohtesh S. Mehta, Nicole M. Kuderer, Veena Shankaran, Stephanie J. Lee, Christopher T. Su
      Abstract: Patients with multiple myeloma (MM) may be on therapy for years, which can lead to financial toxicity (FinTox) or time toxicity (TimeTox). The prevalence, predictors, and quality of life (QOL) impacts of FinTox and TimeTox during different phases of MM treatment have not been characterized.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-02-22
      DOI: 10.1016/j.clml.2024.02.013
       
  • Dampening Logistics Creating Inequitable Access- A Major Threat Despite
           Advancements

    • Free pre-print version: Loading...

      Authors: Fathima Shehnaz Ayoobkhan; Al- Ola Abdallah, Faiz Anwer, Nausheen Ahmed
      Abstract: We read with great interest the recent publication by Shahzad et al. titled “Geographic and Racial Disparities in Chimeric Antigen Receptor–T Cells and Bi-specific Antibodies Trials Access for Diffuse Large B-Cell Lymphoma” which is a report on the distribution across the US of chimeric antigen receptor T cell (CART) and bispecific therapies1. Shahzad et al. demonstrated that the 126 studies were distributed over 31 states, however, there is considerable variation by region in the availability of the trial.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-02-21
      DOI: 10.1016/j.clml.2024.02.011
       
  • SOHO State of the Art Updates and Next Questions: Treatment Evolution of
           Mantle Cell Lymphoma: Navigating the Different Entities and Biological
           Heterogeneity of Mantle Cell Lymphoma in 2024

    • Free pre-print version: Loading...

      Authors: Andrew Ip; Alexandra Della Pia, Andre Goy
      Abstract: Progress in mantle cell lymphoma (MCL) has led to significant improvement in outcomes of patients even in the real world (RW) setting albeit to a lesser degree. In parallel to the demonstration of benefit using combination therapy with rituximab plus high-dose cytarabine (R-AraC) as well as dose intensive therapy-autologous stem cell transplantation (DIT-ASCT) consolidation and maintenance, it became clear over the last 2 decades that MCL is a highly heterogenous disease at the molecular level, explaining differences observed in clinical behavior and response to therapy.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-02-21
      DOI: 10.1016/j.clml.2024.02.010
       
  • SOHO State of the Art Updates & Next Questions Measurable Residual Disease
           in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

    • Free pre-print version: Loading...

      Authors: Nicholas J. Short; Elias Jabbour, Hagop Kantarjian
      Abstract: Assessment of measurable residual disease (MRD) provides important prognostic information and can inform decision-making about appropriate consolidative therapy in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Many contemporary treatment protocols for Ph+ ALL achieve high rates of MRD negativity, and several analyses suggest that allogeneic hematopoietic stem cell transplant in first remission can be safely deferred in most patients who achieve MRD negativity by PCR for BCR::ABL1 within 3 months.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-02-21
      DOI: 10.1016/j.clml.2024.02.009
       
  • Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin
           Lymphoma: A Systematic Review and Meta-Analysis

    • Free pre-print version: Loading...

      Authors: Samuel Yamshon; Caitlin Gribbin, Mohammad Alhomoud, Nora Chokr, Zhengming Chen, Michelle Demetres, Michelle Pasciolla, John Leonard, Tsiporah Shore, Peter Martin
      Abstract: The application of CD19-directed chimeric antigen receptor T (CAR T) cell therapy has improved outcomes for thousands of patients with non-Hodgkin B cell lymphoma (NHL). The toxicities associated with various CAR T cell products, however, can be severe and difficult to anticipate.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-02-16
      DOI: 10.1016/j.clml.2024.02.007
       
  • Comparison of the efficacy among nilotinib, dasatinib, flumatinib and
           imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
           patients: A real-world multi-center retrospective study

    • Free pre-print version: Loading...

      Authors: Xiaoshuai Zhang; Na Xu, Yunfan Yang, Hai Lin, Bingcheng Liu, Xin Du, Xiaoli Liu, Rong Liang, Chunyan Chen, Jian Huang, Huanling Zhu, Ling Pan, Xiaodong Wang, Guohui Li, Zhuogang Liu, Yanqing Zhang, Zhenfang Liu, Jianda Hu, Chunshui Liu, Fei Li, Wei Yang, Li Meng, Yanqiu Han, Li'e Lin, Zhenyu Zhao, Chuanqing Tu, Caifeng Zheng, Yanliang Bai, Zeping Zhou, Suning Chen, Huiying Qiu, Lijie Yang, Xiuli Sun, Hui Sun, Li Zhou, Zelin Liu, Danyu Wang, Jianxin Guo, Liping Pang, Qingshu Zeng, Xiaohui Suo, Weihua Zhang, Yuanjun Zheng, Yanli Zhang, Weiming Li, Qian Jiang
      Abstract: There are limited data comprehensively comparing therapy responses and outcomes among nilotinib, dasatinib, flumatinib and imatinib for newly diagnosed chronic-phase chronic myeloid leukemia in a real-world setting.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-02-14
      DOI: 10.1016/j.clml.2024.02.008
       
  • Treatment Pattern, Healthcare Resource Utilization and Symptom Burden
           Among Patients with Triple Class Exposed Multiple Myeloma: A
           Population-Based Cohort Study

    • Free pre-print version: Loading...

      Authors: Hira Mian; Hsien Seow, Gregory R. Pond, Anastasia Gayowsky, Ronan Foley, Amaris Balistky, Mohammed Ebraheem, Christopher Cipkar, Hyra Sapru, Ghulam Rehman Mohyuddin, Samer Al Hadidi, Alissa Visram
      Abstract: This study aims to describe the treatment patterns, outcomes, health care utilization and symptom burden of triple class exposed (TCE) relapsed/refractory patents with multiple myeloma (MM) receiving a subsequent line of treatment (LOT).
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-02-13
      DOI: 10.1016/j.clml.2024.02.006
       
  • Alternative Dosing Schedules of Azacitidine: a real-world study across
           South American centers

    • Free pre-print version: Loading...

      Authors: Lucas Castelo; Wellington Fernandes da Silva, Marco Lincango, Valeria Buccheri, Agustina Perusini, Jorge Arbelbide, Marcelo Iastrebner, Jacqueline Gonzalez, Patricio Pereyra, Thales Dalessandro M. Pereira, Luan Lima Marchi, Vanderson Rocha, Carolina B. Belli, Elvira Deolinda Rodrigues Pereira Velloso
      Abstract: To the Editor,
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-02-13
      DOI: 10.1016/j.clml.2024.02.003
       
  • Hypomethylating agents and venetoclax for acute myeloid leukemia relapsed
           after hematopoietic stem cell transplant

    • Free pre-print version: Loading...

      Authors: Filip Ionescu; Jerel C David, Apoorva Ravichandran, David A Sallman, Kendra Sweet, Rami S Komrokji, Onyee Chan, Andrew Kuykendall, Eric Padron, Rawan Faramand, Nelli Bejanyan, Farhad Khimani, Hany Elmariah, Joseph Pidala, Asmita Mishra, Lia Perez, Taiga Nishihori, Jeffrey E Lancet
      Abstract: Hypomethylating agent + venetoclax is an effective frontline combination for acute myeloid leukemia, but its efficacy and safety in post-allogeneic hematopoietic cell transplant (alloHCT) relapse remain underexplored. Outcomes have been poor for this population, with no standard treatment.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-02-12
      DOI: 10.1016/j.clml.2024.02.005
       
  • Recent Developments in Convenience of Administration of the Anti-CD38
           Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion
           in Patients With Multiple Myeloma

    • Free pre-print version: Loading...

      Authors: Hang Quach; Gurdeep Parmar, Maria-Victoria Mateos, Sikander Ailawadhi, Xavier Leleu
      Abstract: Isatuximab-based combinations are among the accepted standard-of-care regimens for early-line treatment of patients with relapsed/refractory multiple myeloma (RRMM), based on the results of the Phase 3 ICARIA-MM and IKEMA trials. Further study findings have shown benefit with Isa-based combinations in patients with newly diagnosed MM, as reported from the randomized GMMG-HD7 and CONCEPT trials. Isa is currently approved in various countries for intravenous (IV) administration in patients with RRMM.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-02-12
      DOI: 10.1016/j.clml.2024.02.004
       
  • Long-term follow up of the combination of ofatumumab, high-dose
           methylprednisolone, and lenalidomide for untreated chronic lymphocytic
           leukemia with biomarker analysis

    • Free pre-print version: Loading...

      Authors: Julio C Chavez; Ariel Grajales, Jose Sandoval-Sus, Elyce Turba, Lisa Nodzon, Angimar Uriepero, Mohammad Ammad-Ud-Din, Eva Sahakian, Rami Komrokji, Lubomir Sokol, Frederick L Locke, Bijal Shah, Jeffrey Lancet, Eduardo M Sotomayor, Mohamed A. Kharfan-Dabaja, Celeste Bello, Javier Pinilla-Ibarz
      Abstract: Advancements in frontline therapy and chemotherapy-sparing treatments in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have altered the treatment algorithms of this disease. We present a frontline alternative for treatment- naïve (TN) CLL/SLL patients.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-02-12
      DOI: 10.1016/j.clml.2024.02.001
       
  • Real-world Survival, Healthcare Resource Utilization, and Costs among U.S.
           Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with
           R-GemOx in the Relapsed/Refractory Setting

    • Free pre-print version: Loading...

      Authors: Mahek Garg; Justin Puckett, Sachin Kamal-Bahl, Monika Raut, Katherine Elizabeth Ryland, Jalpa A. Doshi, Scott F. Huntington
      Abstract: Little recent real-world evidence exists on overall survival, healthcare resource utilization (HCRU), and costs among R/R DLBCL patients treated with the combination of rituximab, gemcitabine, and oxaliplatin (R-GemOx), a widely-used regimen for patients ineligible for stem cell transplant due to age or comorbidities.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-02-08
      DOI: 10.1016/j.clml.2024.01.010
       
  • Efficacy and safety of children with relapsed/refractory B-cell acute
           lymphoblastic leukemia after anti-CD19 CAR T-cell therapy without bridging
           transplantation

    • Free pre-print version: Loading...

      Authors: Qianwen Shang; Lian Xue, Aidong Lu, Yueping Jia, YingXi Zuo, Huimin Zeng, Leping Zhang
      Abstract: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapies have demonstrated significant efficacy in achieving complete remission (CR) in pediatric patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). However, a considerable number of patients experience relapse within one year after CAR T-cell therapy, leading to an extremely poor prognosis, particularly in patients without bridging transplantation. In our study, we investigated 42 children with R/R B-ALL who underwent anti-CD19 CAR T-cell therapy without bridging transplantation at our center.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-02-07
      DOI: 10.1016/j.clml.2024.02.002
       
  • Outcome of Patients with Relapsed Acute Promyelocytic Leukemia

    • Free pre-print version: Loading...

      Authors: Koji Sasaki; Farhad Ravandi, Tapan Kadia, Courtney D DiNardo, Musa Yilmaz, Nicholas Short, Elias Jabbour, Keyur P Patel, Sanam Loghavi, Sherry Pierce, Gautam Borthakur, Hagop Kantarjian
      Abstract: The outcome of patients with acute promyelocytic leukemia (APL) has improved significantly since the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) as APL therapies. The optimal therapy for APL relapse is believed to require autologous or allogeneic stem cell transplantation (SCT) based on historical experience.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-02-03
      DOI: 10.1016/j.clml.2024.01.015
       
  • Azacitidine Post-transplant Maintenance Improves Disease Progression in
           High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

    • Free pre-print version: Loading...

      Authors: Oren Pasvolsky; Rima M. Saliba, Uday R. Popat, Amin Alousi, Rohtesh Mehta, Jason Yeh, Gheath Al-Atrash, Masood Adeel, Jeremy Ramdial, David Marin, Gabriela Rondon, Partow Kebriaei, Richard Champlin, Naval Daver, Courtney Dinardo, Nicholas J. Short, Elizabeth J. Shpall, Betül Oran
      Abstract: For patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic transplantation (alloHCT), disease relapse remains the most common reason for transplant failure and patient death1. It has been shown that immune evasion with the emerging selection of subclones resistant to graft versus leukemia effect is one of the most common mechanisms underlying post-transplant relapse. Eloquently designed studies showed that it was not the acquisition of previously unknown disease specific mutations that was leading to the relapse after alloHCT but the downregulation of major histocompatibility complex (MHC) class II genes associated with the relapse2.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-02-02
      DOI: 10.1016/j.clml.2024.01.012
       
  • Optimizing the CAR T-Cell Therapy Experience in Multiple Myeloma: Clinical
           Pearls From an Expert Roundtable

    • Free pre-print version: Loading...

      Authors: Sikander Ailawadhi; Leyla Shune, Sandy W. Wong, Yi Lin, Krina Patel, Sundar Jagannath
      Abstract: Chimeric antigen receptor T-cell (CAR-T) therapies offer substantial advancement in the treatment of multiple myeloma (MM). However, the CAR-T therapy process involves complex decision-making that is informed by many variables. This review aims to provide an overview of the patient selection and administration process for CAR-T therapy for MM from the perspective of experienced healthcare providers (HCPs), including considerations for each step in the CAR-T therapy process. Referring HCPs should initiate conversations with HCPs at CAR-T–capable centers earlier in the treatment journey, even before patients are eligible for CAR-T therapy, particularly for patients from underserved populations and patients with high-risk disease, to ensure adequate time for logistical planning and patient education.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-01-31
      DOI: 10.1016/j.clml.2024.01.014
       
  • Healthcare resource utilization and cost-of-illness in systemic light
           chain (AL) amyloidosis in Europe: results from the real-world,
           retrospective EMN23 study

    • Free pre-print version: Loading...

      Authors: Arnaud Jaccard; Frank Bridoux, Wilfried Roeloffzen, Monique C. Minnema, Rui Bergantim, Roman Hájek, Cristina João, M. Teresa Cibeira, Giovanni Palladini, Stefan Schönland, Giampaolo Merlini, Paolo Milani, Meletios A. Dimopoulos, Sriram Ravichandran, Ute Hegenbart, Hermine Agis, Blanca Gros, Aisha Asra, Valeria Magarotto, Giorgos Cheliotis, Giorgos Psarros, Pieter Sonneveld, Ashutosh Wechalekar, Efstathios Kastritis
      Abstract: Systemic light chain (AL) amyloidosis is a rare clonal disease caused by immunoglobulin light chains that misfold, aggregate, and form amyloid fibrils in several critical organ systems, predominantly in the heart and kidneys (∼70% of patients). 1,2 The crude incidence of AL amyloidosis was 10.44 patients per million population in 2018. 3
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-01-31
      DOI: 10.1016/j.clml.2024.01.013
       
  • A comparison of 3-year follow-up of ZUMA-5 (axicabtagene ciloleucel) with
           SCHOLAR-5 in relapsed/refractory follicular lymphoma

    • Free pre-print version: Loading...

      Authors: Paola Ghione; M Lia Palomba, Markqayne D Ray, Eve Limbrick-Oldfield, Jessica Owen, Steve Kanters, Sabela Bobillo, Maria Teresa Ribiero, Caron A Jacobson, Sattva S Neelapu, Herve Ghesquieres, Myrna Nahas, Sara Beygi, Anik R Patel, John G Gribben
      Abstract: In the pivotal ZUMA-5 trial, axicabtagene ciloleucel (axi-cel; an autologous anti-CD19 chimeric antigen receptor T-cell therapy) demonstrated high rates of durable response in relapsed/refractory follicular lymphoma patients. SCHOLAR-5 is an external control cohort designed to act as a comparator to ZUMA-5. Here, we present an updated comparative analysis of ZUMA-5 and SCHOLAR-5, using the 36-month follow-up data and the intent-to-treat population of ZUMA-5. Using propensity-score methods, 127 patients in ZUMA-5 were compared to 129 patients in SCHOLAR-5.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-01-24
      DOI: 10.1016/j.clml.2024.01.011
       
  • THE ITALIAN MULTICENTRIC RANDOMIZED OPTKIMA TRIAL ON FIXED VS PROGRESSIVE
           INTERMITTENT TKI THERAPY IN CML ELDERLY PATIENTS: 3-YEARS OF MOLECULAR
           RESPONSE AND QUALITY OF LIFE MONITORING AFTER COMPLETING THE TREATMENT
           PLAN.

    • Free pre-print version: Loading...

      Authors: M. Malagola; A. Iurlo, C. Bucelli, E. Abruzzese, M. Bonifacio, F. Stagno, G. Binotto, M. D'Adda, M. Lunghi, M. Crugnola, M.L. Ferrari, F. Lunghi, F. Castagnetti, G. Rosti, R. M Lemoli, R. Sancetta, M.R. Coppi, M.T. Corsetti, M De Gobbi, A. Romano, M. Tiribelli, A. Russo Rossi, S. Russo, M. Defina, M. Farina, S. Bernardi, G. Butturini, S. Pellizzeri, A.M. Roccaro, D. M Russo
      Abstract: Intermittent treatment with TKIs is an option for elderly CML patients who are often candidate to life-long treatment.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-01-24
      DOI: 10.1016/j.clml.2024.01.008
       
  • SOHO State of the Art Updates and Next Questions Diagnosis, Outcomes, and
           Management of Prefibrotic Myelofibrosis

    • Free pre-print version: Loading...

      Authors: Pankit Vachhani; Sanam Loghavi, Prithviraj Bose
      Abstract: Prefibrotic primary myelofibrosis (prefibrotic PMF) is a myeloproliferative neoplasm with distinct characteristics comprising histopathological and clinico-biological parameters. It is classified as a subtype of primary myelofibrosis. In clinical practice, it is essential to correctly distinguish prefibrotic PMF from essential thrombocythemia especially but also overt PMF besides other myeloid neoplasms. Risk stratification and survival outcomes for prefibrotic PMF are worse than that of ET but better than that of overt PMF.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-01-20
      DOI: 10.1016/j.clml.2024.01.009
       
  • Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial

    • Free pre-print version: Loading...

      Authors: Marina Y. Konopleva; Monique Dail, Naval G. Daver, Jacqueline S. Garcia, Brian A. Jonas, Karen W.L. Yee, Kevin R. Kelly, Norbert Vey, Sarit Assouline, Gail J. Roboz, Stefania Paolini, Daniel A. Pollyea, Agostino Tafuri, Joseph M. Brandwein, Arnaud Pigneux, Bayard L. Powell, Pierre Fenaux, Rebecca L. Olin, Giuseppe Visani, Giovanni Martinelli, Maika Onishi, Jue Wang, Weize Huang, Diana Dunshee, Habib Hamidi, Marion G. Ott, Wan-Jen Hong, Michael Andreeff
      Abstract: Acute myeloid leukemia (AML) is an aggressive malignancy, and largely a disease of older patients, with a median age at diagnosis of 68 years.1 Therapies for patients with relapsed or refractory (R/R) AML remain limited and outcomes poor, especially for patients who are ineligible for cytotoxic chemotherapy or targeted therapies.2-6 Therapies that target survival pathways known to be dysregulated or aberrant in AML may improve outcomes, particularly if they are less toxic.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-01-18
      DOI: 10.1016/j.clml.2024.01.007
       
  • Serologic Response to Vaccine for COVID-19 in Patients with Hematologic
           Malignancy: A Prospective Cohort Study

    • Free pre-print version: Loading...

      Authors: Alexandra Hillyer; Anthony Quint, Artin Ghassemian, Nicolette Joh-Carnella, Michael J. Knauer, Danny Dawd, Alejandro Lazo-Langner, Joy Mangel, Selay Lam, Husam Abdoh, Anargyros Xenocostas, Uday Deotare, Lalit Saini, Cheryl Foster, Martha Louzada, Jenny Ho, Ian Chin Yee, Chai W. Phua
      Abstract: Patients with hematologic malignancies have increased mortality due to COVID-19.1 A recent systematic review reported a fatality rate of up to 40% for patients with hematologic cancer and SARS-CoV-2 infection, significantly higher than the 3.6% fatality rate reported in the literature for the general population.2 Vaccination responses are known to be attenuated in patients with hematologic malignancies. Monin et al. reported that 18% of patients with hematologic cancers had positive anti-S IgG titers three weeks after receiving a single dose of the BNT162b2 vaccine compared to 94% of healthy controls and 38% of patients with solid cancers.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-01-18
      DOI: 10.1016/j.clml.2024.01.004
       
  • SOHO State of the Art Updates and Next Questions Will CAR-T Replace ASCT
           in NDMM'

    • Free pre-print version: Loading...

      Authors: Eric Jurgens; Saad Z. Usmani
      Abstract: The treatment landscape for multiple myeloma (MM) has rapidly evolved over the last two decades. The development of triplet and quadruplet regimens including proteasome inhibitors (PI), immunomodulatory agents (IMiDs), and anti-CD38 monoclonal antibodies has dramatically extended overall survival. In addition to effective multidrug regimens, autologous stem cell transplant (ASCT) is a cornerstone of management in newly diagnosed multiple myeloma (NDMM). However, despite these combined treatment modalities, curative therapy for MM remains elusive.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-01-18
      DOI: 10.1016/j.clml.2024.01.001
       
  • Geographic and Racial Disparities in Chimeric Antigen Receptor–T Cells
           and Bi-specific Antibodies Trials Access for Diffuse Large B-Cell Lymphoma
           

    • Free pre-print version: Loading...

      Authors: Moazzam Shahzad; Muhammad Fareed Khalid, Muhammad Kashif Amin, Ahmad Basharat, Mohammad Ammad-Ud-Din, Robin Park, Iqra Anwar, Muhammad Salman Faisal, Michael Jaglal
      Abstract: We investigate the geographical and racial disparities in accessing CAR-T and bispecific antibodies trials for DLBCL. ClinicalTrials.gov was searched, and 75 trials with at least one open site in the US were included. 2020 US Census Bureau data was used to obtain data on race and ethnicity. SPSS version 26 was used for analysis. There were 62 CAR-T and 13 bispecific antibodies trials with 6221 enrolled or expected to enroll patients. 85% of the clinical trials were only open in the US, and the majority 64% were pharmaceutical-funded. There were 126 unique study sites distributed over 31 states with 11 (0-51) mean number of trials per state and 4.5 (1-26) and 4.4 (1-24) mean number of CAR-T and bispecific antibodies trials per site, respectively.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-01-17
      DOI: 10.1016/j.clml.2024.01.006
       
  • Prognostic Impact of Bone Marrow Fibrosis And Effects of Tyrosine Kinase
           Inhibitors on Bone Marrow Fibrosis in Chronic Myeloid Leukemia

    • Free pre-print version: Loading...

      Authors: Mehmet Sezgin Pepeler; Mesut Tıglıoglu, Simten Dagdas, Esra Ozhamacıoglu, Unsal Han, Aynur Albayrak, Mürüvvet Seda Aydın, Gülten Korkmaz, Merve Pamukcuoğlu, Funda Ceran, Murat Albayrak, Gülsüm Ozet
      Abstract: Myelofibrosis is reported in around 40% of newly diagnosed chronic myeloid leukemia (CML) patients and have an important role in the pathobiology and prognosis of CML. This retrospective study aimed to evaluate the effects of bone marrow (BM) fibrosis on disease prognosis and the effects of specific tyrosine-kinase inhibitors (TKIs) on BM fibrosis in CML patients.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-01-16
      DOI: 10.1016/j.clml.2023.12.015
       
  • A review of the therapeutic role of bosutinib in chronic myeloid leukemia

    • Free pre-print version: Loading...

      Authors: H.M. Kantarjian; E.J. Jabbour, J.H. Lipton, F. Castagnetti, T.H. Brümmendorf
      Abstract: The development of the BCR::ABL1 tyrosine kinase inhibitors (TKIs) has transformed Philadelphia chromosome (Ph)–positive chronic myeloid leukemia (CML) from a fatal disease to an often-indolent illness that, when managed effectively, can restore a life expectancy close to that of the normal population. Bosutinib is a second-generation TKI approved for adults with Ph-positive CML in chronic phase, accelerated phase, or blast phase that is resistant or intolerant to prior therapy, and for newly diagnosed Ph-positive chronic phase CML.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-01-11
      DOI: 10.1016/j.clml.2024.01.005
       
  • Chimeric Antigen Receptor T - Cell Therapy for Large B-Cell Lymphoma
           Patients with Central Nervous System Involvement, a Systematic Review and
           Meta-analysis

    • Free pre-print version: Loading...

      Authors: Ghada Elgohary; Yang Yang, Mia Gergis, Dongni Yi, Usama Gergis
      Abstract: Chimeric Antigen Receptor T-cell (CAR T-cell) therapy is an effective treatment for relapsed/refractory (R/R) large B cell lymphoma (LBCL). However, patients with central nervous system (CNS) lymphoma were excluded in most of the CAR T-cell therapy trials. This meta-analysis assesses the efficacy with CAR T-cell therapy in LBCL patients with CNS involvement. Two reviewers independently searched PubMed and Cochrane Library to identify all published literature associated with United States Food and Drug Administration approved CAR T-cell therapies for LBCL.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-01-11
      DOI: 10.1016/j.clml.2023.12.012
       
  • SOHO State of the Art Updates and Next Questions CTLs for Infections
           Following Stem Cell Transplantation

    • Free pre-print version: Loading...

      Authors: Ariel Rischall; Amanda Olson
      Abstract: Allogeneic hematopoietic stem cell transplantation (AHSCT) is an important modality in the treatment of acute leukemia and other hematologic disorders. The post-transplant period is associated with prolonged periods of impaired immune function. Delayed T-cell immune reconstitution is correlated with increased risk of viral, bacterial, and fungal infections. This risk increases with high intensity inductions regimens often required for alternative donor sources. Current therapies for prophylaxis and treatment of these infections are limited by poor efficacy and significant toxicity.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-01-08
      DOI: 10.1016/j.clml.2024.01.003
       
  • SOHO State of the Art Updates and Next Questions Next Questions: Acute
           Lymphoblastic Leukemia

    • Free pre-print version: Loading...

      Authors: Jayastu Senapati; Hagop Kantarjian, Fadi G. Haddad, Nicholas J. Short, Mary Alma Welch, Nitin Jain, Elias Jabbour
      Abstract: The integration of immune and targeted therapies into the treatment of acute lymphoblastic leukemia (ALL) has significantly improved outcomes, reduced the intensity and duration of chemotherapy, and the reliance on allogeneic stem cell transplantation (SCT). In younger patients with Philadelphia chromosome (Ph)-negative ALL, treatment with Hyper-CVAD and blinatumomab +/- inotuzumab has improved the 3-year overall survival (OS) to above 85%. In older patients, using less intensive chemotherapy (mini-Hyper-CVD) in combination with inotuzumab and blinatumomab has improved the 5-year OS rate to 50%.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-01-08
      DOI: 10.1016/j.clml.2023.12.013
       
  • An Open-Label Phase I Study of Metformin and Nelfinavir in Combination
           

    • Free pre-print version: Loading...

      Authors: Ibrahim Alodhaibi; Sikander Ailawadhi, Gabriel P. Burbano, Patrick J. O'Brien, Francis K. Buadi, Suzanne Hayman, Shaji K. Kumar, Wilson I. Gonsalves
      Abstract: A therapeutic combination of metformin, nelfinavir, and bortezomib is feasible for multiple myeloma patients with relapsed and/or refractory disease. While no dose-limiting toxicities were observed, no objective responses were observed either in the dose levels evaluated in this study.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-01-06
      DOI: 10.1016/j.clml.2024.01.002
       
  • Racial Disparities in Mycosis Fungoides/Sézary Syndrome–A Single-Center
           Observational Study of 292 Patients

    • Free pre-print version: Loading...

      Authors: Ashley R. Gandham; Shamir Geller, Stephen W. Dusza, Thomas S. Kupper, Patricia. L. Myskowski
      Abstract: Racial disparities in incidence, demography and outcomes are seen in mycosis fungoides / Sezary syndrome. We report worse survival in black patients compared to white patients with different survival risk for hypopigmentation, erythroderma and ulceration between the races. The underlying mechanisms require further investigation and may have impact on treatment strategies in these groups.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2024)
      PubDate: 2024-01-03
      DOI: 10.1016/j.clml.2023.12.017
       
  • Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves
           Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute
           Lymphoblastic Leukemia

    • Free pre-print version: Loading...

      Authors: Nicholas J. Short; Elias Jabbour, Trevor Jamison, Shilpa Paul, Branko Cuglievan, David McCall, Amber Gibson, Nitin Jain, Fadi G. Haddad, Lewis F. Nasr, Kayleigh R. Marx, Caitlin Rausch, J. Michael Savoy, Rebecca Garris, Farhad Ravandi, Hagop Kantarjian
      Abstract: We retrospectively analyzed the outcomes of patients with B-cell acute lymphoblastic leukemia (ALL) who received a dose-dense regimen of mini-hyper-CVD, inotuzumab ozogamicin and blinatumomab. In newly diagnosed or measurable residual disease (MRD)-positive ALL, 10/11 patients (91%) achieved next-generation sequencing (NGS) MRD negativity at a sensitivity of 10−6, and 6/10 patients (60%) achieved NGS MRD negativity after cycle 1. The regimen was safe and resulted in high rates of deep and rapid MRD negativity, warranting prospective evaluation.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2023)
      PubDate: 2023-12-29
      DOI: 10.1016/j.clml.2023.12.016
       
  • Second Treatment-Free Remission Attempt in Patients with Chronic Myeloid
           Leukemia

    • Free pre-print version: Loading...

      Authors: Hiroshi Ureshino; Kazuharu Kamachi, Shinya Kimura
      Abstract: Long-term survival outcomes of patients with chronic myeloid leukemia in the chronic phase are now similar to those of the general population, following the introduction of ABL1 tyrosine kinase inhibitors (TKIs). Approximately 40% to 80% of patients with chronic myeloid leukemia successfully achieved treatment-free remission after the first attempt of TKI discontinuation (TFR1), after achieving a durable deep molecular response. However, the possibility of achieving treatment-free remission after a second attempt of TKI discontinuation (TFR2) remains unclear.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2023)
      PubDate: 2023-12-28
      DOI: 10.1016/j.clml.2023.12.011
       
  • Effect of Tyrosine Kinase Inhibitor Therapy on Estimated Glomerular
           Filtration Rate in Patients with Chronic Myeloid Leukemia

    • Free pre-print version: Loading...

      Authors: Özge Sönmez; Nurgül Özgür Yurttaş, İlker İhtiyaroğlu, HalilMete Çakır, Zeynep Atlı, Tuğrul Elverdi, Ayşe Salihoğlu, Nurhan Seyahi, Muhlis Cem Ar, Şeniz Öngören, Zafer Başlar, Teoman Soysal, Ahmet Emre Eşkazan
      Abstract: The advent of tyrosine kinase inhibitors (TKIs) was revolutionary in the management of chronic myeloid leukemia (CML). Although TKIs were generally considered to be safe, they can be associated with renal injury. We evaluated the effect of TKIs on renal functions in a cohort of patients with long-term follow-up.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2023)
      PubDate: 2023-12-27
      DOI: 10.1016/j.clml.2023.12.004
       
  • Epidemiologic characteristics, treatment patterns, and survival analysis
           of Plasmablastic Lymphoma in the US: A SEER and NCDB analysis.

    • Free pre-print version: Loading...

      Authors: Alec R. Hansen; Victoria A. Vardell, Lindsey A. Fitzgerald
      Abstract: Plasmablastic lymphoma is a rare lymphoma associated with poor survival. We evaluated over 1,800 patients using SEER and the NCDB. Among treated patients, we described an unprecedented median overall survival of 58.6 months, and demonstrated a survival benefit for patients treated with multiagent chemotherapy. These findings will help guide clinical advances aimed at improving therapeutic options and survival outcomes for patients.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2023)
      PubDate: 2023-12-25
      DOI: 10.1016/j.clml.2023.12.014
       
  • Utilization of Autologous Hematopoietic Cell Transplantation Over Time in
           Multiple Myeloma: A Population-Based Study

    • Free pre-print version: Loading...

      Authors: Naseem S. Esteghamat; Ann Brunson, Aaron S. Rosenberg, Sara J. Schonfeld, Bryan Valcarcel, Renata Abrahão, Julianne J.P. Cooley, Christa L. Meyer, Jeffery J. Auletta, Lindsay M. Morton, Lori Muffly, Ted Wun, Theresa H.M. Keegan
      Abstract: Autologous hematopoietic cell transplantation (autoHCT) is associated with survival benefits in multiple myeloma (MM), but utilization remains low and differs by sociodemographic factors. Prior population-based studies have not fully captured autoHCT utilization or examined relationships between sociodemographic factors and autoHCT trends over time.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2023)
      PubDate: 2023-12-19
      DOI: 10.1016/j.clml.2023.12.009
       
  • Recent Advances in the Biology and CD123-Directed Treatment of Blastic
           Plasmacytoid Dendritic Cell Neoplasm

    • Free pre-print version: Loading...

      Authors: Naveen Pemmaraju; Eric Deconinck, Priyanka Mehta, Irwin Walker, Marco Herling, Francine Garnache-Ottou, Nadia Gabarin, Clinton J.V. Campbell, Johannes Duell, Yakir Moshe, Tariq Mughal, Mohamad Mohty, Emanuele Angelucci
      Abstract: acute lymphoblastic leukemiaallo, allogeneic
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2023)
      PubDate: 2023-12-19
      DOI: 10.1016/j.clml.2023.12.010
       
  • Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With
           Higher-risk Myelodysplastic Syndromes

    • Free pre-print version: Loading...

      Authors: Nishanthan Rajakumaraswamy; Mitul Gandhi, Andrew H. Wei, David A. Sallman, Naval G. Daver, Shuyuan Mo, Shahed Iqbal, Roshan Karalliyadda, Manli Chen, Yunfei Wang, Paresh Vyas
      Abstract: Azacitidine (AZA) is an approved frontline therapy for higher-risk myelodysplastic syndromes (HR-MDS); however, poor survival denotes unmet needs to increase depth/duration of response (DOR).
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2023)
      PubDate: 2023-12-19
      DOI: 10.1016/j.clml.2023.12.008
       
  • SOHO State of the Art Updates and Next Questions: Update on the Approach
           to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

    • Free pre-print version: Loading...

      Authors: Fadi G. Haddad; Elias Jabbour, Nicholas J. Short, Nitin Jain, Hagop Kantarjian
      Abstract: The outcome of Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) has improved significantly following the introduction of the BCR::ABL1 tyrosine kinase inhibitors (TKIs). The addition of newer-generation and more potent TKIs resulted in higher rates of molecular responses and better survival. Achieving a complete molecular remission (CMR; disappearance of the BCR::ABL1 transcripts) within the first three months of therapy is an important endpoint in newly diagnosed Ph-positive ALL that identifies patients who have an excellent long-term survival and who may not need to receive an allogeneic hematopoietic stem cell transplantation (HSCT) in first complete remission (CR).
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2023)
      PubDate: 2023-12-13
      DOI: 10.1016/j.clml.2023.12.007
       
  • Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell
           Non-Hodgkin Lymphoma: Clinical Management Experience from a Pivotal Phase
           I/II Trial

    • Free pre-print version: Loading...

      Authors: Matthew Matasar; Nancy L. Bartlett, Mazyar Shadman, Lihua E. Budde, Ian Flinn, Gareth P. Gregory, Won Seog Kim, Georg Hess, Dima El-Sharkawi, Catherine S. Diefenbach, Huang Huang, Iris To, Joana Parreira, Mei Wu, Antonia Kwan, Sarit Assouline
      Abstract: Mosunetuzumab is a CD20xCD3 T-cell engaging bispecific antibody approved in Europe and the United States for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2023)
      PubDate: 2023-12-11
      DOI: 10.1016/j.clml.2023.12.005
       
  • SOHO State of the Art Updates and Next Questions Chronic Myeloid Leukemia
           and Pregnancy: “Per Aspera Ad Astra”

    • Free pre-print version: Loading...

      Authors: Elisabetta Abruzzese; Malgorzata Monika Trawinska, Paolo De Fabritiis, Simona Bernardi
      Abstract: Chronic myeloid leukemia (CML) has evolved from an invariably fatal disease to a chronic disorder that can be treated with targeted drugs and allows survival expectations approaching age-matched controls. Thus, pregnancy and conception in CML should not be precluded anymore; however, to ensure the well-being of both the mother and the developing fetus careful planning and management are required. Tyrosine Kinase Inhibitors (TKIs) are not genotoxic or carcinogenic but can pose a risk to the developing fetus, due to their teratogenic potential.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2023)
      PubDate: 2023-12-11
      DOI: 10.1016/j.clml.2023.11.011
       
  • Immunoglobulin high throughput sequencing (Ig-HTS) minimal residual
           disease (MRD) analysis is an effective surveillance tool in patients with
           mantle cell lymphoma

    • Free pre-print version: Loading...

      Authors: Alexandra Rezazadeh; Julie Pruett, Amy Detzner, Natasha Edwin, Mehdi Hamadani, Nirav N. Shah, Timothy S. Fenske
      Abstract: Mantle cell lymphoma accounts for 4-6% of B-cell non-Hodgkin lymphoma (NHL) with historically poor outcomes. With the advent of intensive first-line, targeted, and cellular therapies, outcomes have improved, and initial remission can be 8-10 years or even longer. As patients experience longer remissions, this raises the question of the optimal surveillance modality. Peripheral blood minimal residual disease (MRD) analysis offers a potential alternative to surveillance imaging that sensitive, less costly, and eliminates the risk of radiation exposure.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2023)
      PubDate: 2023-12-09
      DOI: 10.1016/j.clml.2023.12.006
       
  • Characterization and Outcomes of Spanish Patients With Relapsed/Refractory
           Multiple Myeloma Included in the LocoMMotion Study

    • Free pre-print version: Loading...

      Authors: Maria-Victoria Mateos; Katja Weisel, Joris Diels, Alberto Arribas, Maria Tamayo, Jordan M. Schecter, Tito Roccia, Imène Haddad, Lida Pacaud, Philippe Moreau
      Abstract: Despite treatment advances that have improved patient survival, including immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti-CD38 monoclonal antibodies (mAbs), multiple myeloma (MM) remains incurable.1,2 Most patients ultimately relapse or become refractory to standard drug classes.3,4 Triple-class exposed patients with relapsed/refractory MM (RRMM) have particularly aggressive disease and a poor prognosis.5 This may, in part, be due to the increasing genetic complexity and more drug-resistant mutations that occur with each new line of therapy (LOT), particularly for patients with high-risk cytogenetics.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2023)
      PubDate: 2023-12-06
      DOI: 10.1016/j.clml.2023.12.001
       
  • FOLINIC ACID OVER - RESCUE OF INTERMEDIATE DOSE METHOTREXATE

    • Free pre-print version: Loading...

      Authors: Ian J Cohen
      Abstract: Dear Sir,
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2023)
      PubDate: 2023-12-04
      DOI: 10.1016/j.clml.2023.12.003
       
  • SOHO State of the Art Updates and Next Questions Oral Therapy in Acute
           Myeloid Leukemia

    • Free pre-print version: Loading...

      Authors: Patrice Nasnas; Farhad Ravandi
      Abstract: With the recent development of several new effective agents, treatment of patients with acute myeloid leukemia (AML) is evolving. Molecularly targeted agents developed against leukemogenic pathways are demonstrating significant promise both as monotherapy and in combination with standard regimens. Although oral chemotherapeutic agents have long been used in the treatment of various malignancies, their use in patients with AML has been hitherto limited. The availability of most newly approved targeted agents in oral formulation has provided us with the potential for developing all oral regimens in AML.
      Citation: Clinical Lymphoma, Myeloma and Leukemia (2023)
      PubDate: 2023-12-01
      DOI: 10.1016/j.clml.2023.11.009
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 44.213.60.33
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-
JournalTOCs
 
 
  Subjects -> MEDICAL SCIENCES (Total: 8186 journals)
    - ALLERGOLOGY AND IMMUNOLOGY (205 journals)
    - ANAESTHESIOLOGY (105 journals)
    - CARDIOVASCULAR DISEASES (334 journals)
    - CHIROPRACTIC, HOMEOPATHY, OSTEOPATHY (19 journals)
    - COMMUNICABLE DISEASES, EPIDEMIOLOGY (227 journals)
    - DENTISTRY (266 journals)
    - DERMATOLOGY AND VENEREOLOGY (162 journals)
    - EMERGENCY AND INTENSIVE CRITICAL CARE (121 journals)
    - ENDOCRINOLOGY (149 journals)
    - FORENSIC SCIENCES (43 journals)
    - GASTROENTEROLOGY AND HEPATOLOGY (178 journals)
    - GERONTOLOGY AND GERIATRICS (125 journals)
    - HEMATOLOGY (160 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (178 journals)
    - LABORATORY AND EXPERIMENTAL MEDICINE (90 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2230 journals)
    - NURSES AND NURSING (331 journals)
    - OBSTETRICS AND GYNECOLOGY (199 journals)
    - ONCOLOGY (355 journals)
    - OPHTHALMOLOGY AND OPTOMETRY (135 journals)
    - ORTHOPEDICS AND TRAUMATOLOGY (150 journals)
    - OTORHINOLARYNGOLOGY (76 journals)
    - PATHOLOGY (96 journals)
    - PEDIATRICS (254 journals)
    - PHYSICAL MEDICINE AND REHABILITATION (153 journals)
    - PSYCHIATRY AND NEUROLOGY (800 journals)
    - RADIOLOGY AND NUCLEAR MEDICINE (182 journals)
    - RESPIRATORY DISEASES (109 journals)
    - RHEUMATOLOGY (76 journals)
    - SPORTS MEDICINE (77 journals)
    - SURGERY (388 journals)
    - UROLOGY, NEPHROLOGY AND ANDROLOGY (151 journals)

HEMATOLOGY (160 journals)                     

Showing 1 - 122 of 122 Journals sorted alphabetically
Acta Angiologica     Open Access   (Followers: 3)
Adipocyte     Open Access  
Advances in Hematology     Open Access   (Followers: 13)
Africa Sanguine     Full-text available via subscription  
American Journal of Hematology     Hybrid Journal   (Followers: 46)
Anemia     Open Access   (Followers: 6)
Annals of Hematology     Hybrid Journal   (Followers: 14)
Arteriosclerosis, Thrombosis and Vascular Biology     Full-text available via subscription   (Followers: 25)
Artery Research     Hybrid Journal   (Followers: 4)
Artificial Cells, Nanomedicine and Biotechnology     Hybrid Journal   (Followers: 3)
ASAIO Journal     Hybrid Journal   (Followers: 2)
Best Practice & Research Clinical Haematology     Hybrid Journal   (Followers: 5)
Blood     Hybrid Journal   (Followers: 296)
Blood Advances     Open Access   (Followers: 9)
Blood and Lymphatic Cancer : Targets and Therapy     Open Access   (Followers: 7)
Blood Cancer Journal     Open Access   (Followers: 21)
Blood Cells, Molecules, and Diseases     Hybrid Journal   (Followers: 5)
Blood Coagulation & Fibrinolysis     Hybrid Journal   (Followers: 27)
Blood Pressure     Open Access   (Followers: 1)
Blood Pressure Monitoring     Hybrid Journal   (Followers: 2)
Blood Reviews     Hybrid Journal   (Followers: 20)
BMJ Open Diabetes Research & Care     Open Access   (Followers: 23)
Bone Marrow Transplantation     Hybrid Journal   (Followers: 15)
British Journal of Haematology     Hybrid Journal   (Followers: 54)
Canadian Journal of Diabetes     Hybrid Journal   (Followers: 9)
Case Reports in Hematology     Open Access   (Followers: 10)
Clinical and Applied Thrombosis/Hemostasis     Open Access   (Followers: 28)
Clinical Diabetes     Full-text available via subscription   (Followers: 30)
Clinical Diabetes and Endocrinology     Open Access   (Followers: 14)
Clinical Lymphoma & Myeloma     Full-text available via subscription   (Followers: 2)
Conquest : The Official Journal of Diabetes Australia     Full-text available via subscription   (Followers: 1)
Current Angiogenesis     Hybrid Journal   (Followers: 1)
Current Diabetes Reports     Hybrid Journal   (Followers: 14)
Current Diabetes Reviews     Hybrid Journal   (Followers: 13)
Current Hematologic Malignancy Reports     Hybrid Journal   (Followers: 2)
Current Opinion in Hematology     Hybrid Journal   (Followers: 14)
Cytotherapy     Full-text available via subscription   (Followers: 1)
Der Diabetologe     Hybrid Journal  
Diabetes     Full-text available via subscription   (Followers: 262)
Diabetes aktuell     Hybrid Journal   (Followers: 2)
Diabetes and Vascular Disease Research     Hybrid Journal   (Followers: 8)
Diabetes Care     Full-text available via subscription   (Followers: 285)
Diabetes Case Reports     Open Access  
Diabetes Educator     Hybrid Journal   (Followers: 10)
Diabetes Research and Clinical Practice     Hybrid Journal   (Followers: 18)
Diabetes Spectrum     Full-text available via subscription   (Followers: 14)
Diabetes Technology & Therapeutics     Hybrid Journal   (Followers: 8)
Diabetes Therapy     Open Access   (Followers: 13)
Diabetic Foot & Ankle     Open Access   (Followers: 9)
Diabetic Medicine     Hybrid Journal   (Followers: 93)
Diabetologia     Hybrid Journal   (Followers: 107)
Diabetologie und Stoffwechsel     Hybrid Journal  
Egyptian Journal of Hematology and Bone Marrow Transplantation     Open Access   (Followers: 9)
eJHaem     Open Access   (Followers: 1)
European Journal of Haematology     Hybrid Journal   (Followers: 12)
Experimental Hematology     Hybrid Journal   (Followers: 3)
Experimental Hematology & Oncology     Open Access   (Followers: 6)
Expert Review of Hematology     Hybrid Journal   (Followers: 4)
Fluids and Barriers of the CNS     Open Access   (Followers: 1)
Haematologica - the Hematology journal     Open Access   (Followers: 35)
Haemophilia     Hybrid Journal   (Followers: 15)
Hematologia     Full-text available via subscription   (Followers: 3)
Hematology     Open Access   (Followers: 9)
Hematology, Transfusion and Cell Therapy     Open Access   (Followers: 2)
Hemodialysis International     Hybrid Journal   (Followers: 3)
Hepatitis Monthly     Open Access   (Followers: 3)
Immunohematology : Journal of Blood Group Serology and Molecular Genetics     Hybrid Journal   (Followers: 3)
Indian Journal of Hematology and Blood Transfusion     Hybrid Journal   (Followers: 1)
Info Diabetologie     Full-text available via subscription  
InFo Hämatologie + Onkologie : Interdisziplinäre Fortbildung von Ärzten für Ärzte     Full-text available via subscription  
Integrated Blood Pressure Control     Open Access   (Followers: 1)
International Blood Research & Reviews     Open Access  
International Journal of Clinical Transfusion Medicine     Open Access   (Followers: 3)
International Journal of Diabetes in Developing Countries     Hybrid Journal   (Followers: 5)
International Journal of Diabetes Research     Open Access   (Followers: 6)
International Journal of Hematology     Hybrid Journal   (Followers: 3)
International Journal of Hematology Research     Open Access   (Followers: 2)
International Journal of Laboratory Hematology     Hybrid Journal   (Followers: 24)
JMIR Diabetes     Open Access  
Journal of Blood Medicine     Open Access  
Journal of Cerebral Blood Flow & Metabolism     Hybrid Journal   (Followers: 3)
Journal of Diabetes     Open Access   (Followers: 12)
Journal of Diabetes and its Complications     Hybrid Journal   (Followers: 13)
Journal of Diabetes and Metabolic Disorders     Open Access   (Followers: 6)
Journal of Diabetes Investigation     Open Access   (Followers: 6)
Journal of Diabetes Mellitus     Open Access   (Followers: 4)
Journal of Hematological Malignancies     Open Access  
Journal of Hematology and Transfusion Medicine     Open Access   (Followers: 1)
Journal of Hematopathology     Hybrid Journal   (Followers: 3)
Journal of Pediatric Hematology/Oncology     Hybrid Journal   (Followers: 6)
Journal of Social Health and Diabetes     Open Access  
Journal of Thrombosis and Haemostasis     Hybrid Journal   (Followers: 52)
Journal of Thrombosis and Thrombolysis     Hybrid Journal   (Followers: 30)
Leukemia     Hybrid Journal   (Followers: 23)
Leukemia and Lymphoma     Hybrid Journal   (Followers: 13)
Leukemia Research     Hybrid Journal   (Followers: 9)
Leukemia Research Reports     Open Access   (Followers: 1)
Leukemia Supplements     Full-text available via subscription  
Nederlands Tijdschrift voor Diabetologie     Hybrid Journal  
Nutrition & Diabetes     Open Access   (Followers: 18)
Oncohematology     Open Access   (Followers: 1)
Open Diabetes Journal     Open Access  
Open Hematology Journal     Open Access   (Followers: 1)
Open Hypertension Journal     Open Access  
Open Journal of Blood Diseases     Open Access  
Pediatric Blood & Cancer     Hybrid Journal   (Followers: 6)
Pediatric Hematology Oncology Journal     Open Access   (Followers: 3)
Peritoneal Dialysis International     Hybrid Journal  
Plasmatology     Open Access   (Followers: 1)
Platelets     Hybrid Journal   (Followers: 2)
Practical Diabetes     Hybrid Journal   (Followers: 4)
Primary Care Diabetes     Hybrid Journal   (Followers: 16)
Research and Practice in Thrombosis and Haemostasis     Open Access   (Followers: 2)
Revista Cubana de Hematología, Inmunología y Hemoterapia     Open Access  
Seminars in Hematology     Hybrid Journal   (Followers: 9)
Seminars in Thrombosis and Hemostasis     Hybrid Journal   (Followers: 28)
The Lancet Haematology     Full-text available via subscription   (Followers: 43)
Therapeutic Advances in Hematology     Hybrid Journal  
Thrombosis & Haemostasis     Hybrid Journal   (Followers: 105)
Thrombosis Research     Hybrid Journal   (Followers: 30)
Transplantation and Cellular Therapy     Hybrid Journal   (Followers: 11)
Veins and Lymphatics     Open Access   (Followers: 1)

           

Similar Journals
Similar Journals
HOME > Browse the 73 Subjects covered by JournalTOCs  
SubjectTotal Journals
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 44.213.60.33
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-